Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management

JOURNAL OF HEPATOLOGY

卷:59

Review

Peveling-Oberhag, Jan¹  Arcaini, Luca^2,3  Hansmann, Martin-Leo⁴  Zeuzem, Stefan¹ 

[1] JW Goethe Univ Hosp, Dept Internal Med, Frankfurt, Germany

[2] Univ Pavia, Dept Hematol Oncol, Fdn IRCCS Policlin San Matteo, I-27100 Pavia, Italy

[3] Univ Pavia, Dept Mol Med, I-27100 Pavia, Italy

[4] Goethe Univ Frankfurt, Senckenberg Inst Pathol, D-60054 Frankfurt, Germany

关键词: Hepatitis C;    Lymphoma;    Antiviral therapy;    B-cell;    Non-Hodgkin lymphoma;   

DOI  :  10.1016/j.jhep.2013.03.018

来源: Elsevier

【 摘 要 】

There is ample epidemiologic evidence for an association of chronic hepatitis C virus (HCV) infection with B-cell non-Hodgkin lymphoma (B-NHL). B-NHL subtypes most frequently associated with HCV are marginal zone lymphoma and diffuse large B-cell lymphoma. The most convincing evidence for a causal relationship between HCV infection and lymphoma development is the observation of B-NHL regression after HCV eradication by antiviral therapy (AVT). In fact, for indolent HCV-associated B-NHL, first-line AVT instead of standard immune-chemotherapy might be considered. Molecular mechanisms of HCV-NHL development are still poorly understood. Three general theories have emerged to understand the HCV-induced lymphomagenesis: (1) continuous external stimulation of lymphocyte receptors by viral antigens and consecutive proliferation; (2) HCV replication in B cells with oncogenic effect mediated by intracellular viral proteins; (3) permanent B-cell damage, e.g., mutation of tumor suppressor genes, caused by a transiently intracellular virus (hit and run theory). This review systematically summarizes the data on epidemiology, interventional studies, and molecular mechanisms of HCV-associated B-NHL. (C) 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

【 授权许可】

Free